nivolumab (opdivo0) as adjuvant therapy for stage III and stage IV melanoma

首页> 外文期刊>Prescrire international >nivolumab (opdivo0) as adjuvant therapy for stage III and stage IV melanoma

【24h】

nivolumab (opdivo0) as adjuvant therapy for stage III and stage IV melanoma

机译：Nivolumab（Opdivo0）作为阶段III和阶段IV黑色素瘤的辅助治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In a trial versus ipilimumab, the 3-year recurrence rate was 13 percentage points lower in the nivolumab group, but precise survival results are lacking. Efficacy has not been demonstrated in patients with distant metas-tases. Nivolumab has potentially serious adverse effects. The first-choice treatment for patients with melanoma with lymph node involvement is surgical excision. If the patient has distant metastases, their excision should also be considered when operable and few in number (1,2). Local or distant recurrence is common after surgical excision (3,4). Antineoplastic therapy after surgery (i.e. adjuvant treatment) is aimed at eradicating any residual cancer cells, in order to reduce the risk of recurrence and extend survival (see "Dabrafenib and trametinib combined, as adjuvant therapy for stage III melanoma" pp. 147-149 and "Pembrolizumab as adjuvant therapy for stage III melanoma" p. 149).

机译：在一项与伊普利单抗对照的试验中，nivolumab组的3年复发率降低了13个百分点，但缺乏精确的生存结果。对远处转移酶患者的疗效尚未得到证实。Nivolumab具有潜在的严重副作用。对于淋巴结受累的黑色素瘤患者，首选的治疗方法是手术切除。如果患者有远处转移，手术时也应考虑切除，数量较少（1,2）。手术切除后局部或远处复发很常见（3,4）。术后抗肿瘤治疗（即辅助治疗）旨在清除任何残留癌细胞，以降低复发风险并延长生存期（见“达布非尼和曲美替尼联合，作为III期黑色素瘤的辅助治疗”第147-149页和“彭布罗利珠单抗作为III期黑色素瘤的辅助治疗”第149页）。

著录项

来源
《Prescrire international》 |2020年第216期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study [J] . Yokota Kenji, Uchi Hiroshi, Uhara Hisashi, The Journal of dermatology . 2019,第12期

机译：辅助治疗与Nivolumab与Ipilimalab进行完全切除阶段III / IV黑色素瘤：日本亚组分析来自第3阶段的238研究
2. A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence [J] . Jeffrey Weber, Jean-Jaques Grob, Kim A Margolin, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：对具有高复发风险的患者（pts）完全切除IIIb / c期或IV期黑色素瘤（MEL）后，使用nivolumab（NIVO）与ipilimumab（IPI）进行辅助免疫疗法的III期研究（CheckMate 238）
3. Adjuvant Treatment of Stage III and IV Melanoma Seeking a Cure with Nivolumab for Patients with BRAF-mutated and BRAF-Wild-type-Tumors [J] . Schmale Ine Oncology research and treatment. . 2020,第9期

机译：辅助治疗III阶段和IV黑色素瘤的治疗，用于患有BRAF突变和BRAF-野生型肿瘤的患者
4. The Role of Adjuvant Therapy for Stage I Seminoma and Nonseminoma of the Testis [C] . Thomas Powles Genitourinary Cancers Symposium . 2012

机译：佐剂治疗对I阶段的作用睾丸阶段和睾丸非狂犬瘤的作用
5. Impact of androgen deprivation therapy on quality of life in men with stage IV prostate cancer. [D] . Withrow, Susanne. 2016

机译：雄激素剥夺治疗对IV期前列腺癌男性生活质量的影响。
6. A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence [O] . Jeffrey Weber, Jean-Jaques Grob, Kim A Margolin, 2015

机译：对具有高复发风险的患者（pts）完全切除IIIb / c期或IV期黑色素瘤（MEL）后使用nivolumab（NIVO）与ipilimumab（IPI）进行辅助免疫治疗的III期研究（CheckMate 238）
7. A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence [O] . 2015

机译：对具有高复发风险的患者（pts）完全切除IIIb / c期或IV期黑色素瘤（MEL）后，使用nivolumab（NIVO）与ipilimumab（IPI）进行辅助免疫治疗的III期研究（CheckMate 238）
8. Experimental investigation of an axial-flow compressor inlet stage operating at transonic relative inlet Mach numbers IV : stage and blade-row performance of stage with axial-discharge stators [R] . Sandercock, Donald M, Lieblein, Seymour, Schwenk, Francis C 1954

机译：在跨音速相对入口马赫数下运行的轴流压气机进气级的实验研究第四阶段：轴向排气定子级的阶段和叶片排性能

nivolumab (opdivo0) as adjuvant therapy for stage III and stage IV melanoma

摘要

著录项

相似文献

相关主题

期刊订阅